

INDEPENDENT AUDITOR'S REPORT

To,
The Members of Q Line Biotech Private Limited (Formerly known as POCT Services Private Limited),

Report on the Consolidated Financial Statements

Opinion

We have audited the accompanying financial statements of **Q Line Biotech Private Limited (Formerly known as POCT Services Private Limited)** (hereinafter referred to as "the Holding Company") and one of its **Associate Company- POCT Science House Pvt. Ltd.** (the Holding Company and its Associate together hereinafter referred to as "the Group") which comprise the Consolidated Balance Sheet as at 31 March 2022, The Consolidated Statement of Profit and Loss for the year then ended, and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

Management's Responsibility for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation of the consolidated financial statements in terms of the requirements of the Companies Act, 2013 ("the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group including its Associate and is in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section



Mayank Mehrotra & Associates

CHARTERED ACCOUNTANTS

316, Murli Bhawan, 10A Ashok Marg, Lucknow P. No.: 4108839 / 9935599100

EMAIL-ID- camayankmehrotra@gmail.com

143(10) of the Companies Act 2013. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Group in preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Group has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Directors, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in sub-paragraph (a) & (c) of the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion


In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group, its associates as at 31.03.2022, and their consolidated profit/loss and their consolidated cash flows for the year ended on that date.

Other Matters

We have audited the financial statements / financial information of **POCT Science House Pvt. Ltd.** (Associates Company). The consolidated financial statements also include the Group's share of net profit/loss of **Rs.15,14,47,419.31** for the year ended 31st March, 2022, in respect of **POCT Science House Pvt. Ltd.** (Associates Company), whose financial statements / financial information have been audited by us. Our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of Associates is based on the reports of the Associate Company

Report on Other Legal and Regulatory Requirements

1. As required by Section 143 (3) of the Act, we report to the extent applicable, that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - b) in our opinion proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the report of the other auditor;



- c) the Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;
 - d) in our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
 - e) on the basis of the written representations received from the directors of the Holding Company as on 31 March 2022 taken on record by the Board of Directors of the Holding Company and the Subsidiary company and the report of the statutory auditors of its associate company, none of the directors of the Group companies and its associate company is disqualified as on 31st March 2022 from being appointed as a director of that Company in terms of Section 164 (2) of the Act;
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure A"; and
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us and the other auditors:
 - i. As per information furnished to us there is no pending litigation which has a financial impact and has not been disclosed in financial statement of the Group.
 - ii. The Group and its associates did not have any material foreseeable losses on long-term contracts including derivative contracts.
- iii. There is no such amount required to be transferred, to the Investor Education and Protection Fund by the Group.

Date: 06/09/2022
Place: Lucknow
UDIN: 22406804BCCTKV8502

For Mayank Mehrotra & Associates
Chartered Accountants
Firm's Registration No. 022941C


(Mayank Mehrotra)
Membership No. - 406804

“Annexure A” to the Independent Auditor’s Report of even date on the Consolidated Financial Statements of Q LINE BIOTECH PRIVATE LIMITED (FORMERLY KNOWN AS POCT SERVICES PRIVATE LIMITED)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013.

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31 March 2022, we have audited the internal financial controls over financial reporting of Q Line Biotech Private Limited (Formerly known as POCT Services Private Limited) (“the Holding Company”) and its associate company which is a company incorporated in India, as of that date. A separate report of IFC is being given by us as the Auditors of the Associate Company of the Group.

Management’s Responsibility for Internal Financial Controls

The Respective Board of Directors of the Holding Company and its Associate Company which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence amount the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and operating effectiveness of internal control based on the assessed risk. The procedures selected depend upon on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial



statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issues by the Institute of Chartered Accountants of India.

Date : 06/09/2022
Place : LUCKNOW
UDIN: 22406804BCCTKV8502

FOR MAYANK MEHROTRA & ASSOCIATES
(Chartered Accountants)
Reg No. :022941C



STATEMENT OF BALANCE SHEET

Name of the company - M/S Q-LINE BIOTECH PRIVATE LIMITED
(Formerly known as M/s POCT Services Pvt. Ltd.)
Consolidated Balance Sheet for the year ended 31st March, 2022

In Lakh (₹)
31/03/2022

In Lakh (₹)
31/03/2021

Particulars	Note No	Figures as at the end of current reporting period	Figures as at the end of current reporting period
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	1	157.50	156.00
(b) Reserves and Surplus	2	10,042.71	4,556.87
(c) Money received against share warrants			
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
(a) Long-term borrowings	3	1,001.33	694.64
(b) Deferred tax liabilities (Net)			
(c) Other Long term liabilities			
(d) Long term provisions			
(4) Current Liabilities			
(a) Short-term borrowings	4	3,341.60	1,872.34
(b) Trade payables			
i) MSME			
ii) NON MSME	5	3,466.06	1,905.37
(c) Other current liabilities	6	558.98	449.37
(d) Short-term provisions	7	629.50	318.60
Total		19,197.69	9,953.19
II. Assets			
(1) Non-current assets			
(a) Property, plant and equipment and Intangible assets			
(i) Property, plant and equipment	8	940.04	744.35
(b) Non-current investments			
(c) Deferred tax assets (net)		14.68	14.68
(d) Long term loans and advances	9	628.19	196.32
(e) Other non-current assets			
(2) Current assets			
(a) Current investments	10	757.24	-
(b) Inventories	11	3,762.59	3,120.35
(c) Trade receivables	12	4,303.45	3,025.88
(d) Cash and cash equivalents	13	4,653.71	275.91
(e) Short-term loans and advances			
(f) Other current assets	14	4,137.79	2,575.71
Total		19,197.69	9,953.19

AUDIT REPORT

" AS PER OUR SEPARATE REPORT OF EVEN DATE ANNEXED"

FOR MAYANK MEHROTRA & ASSOCIATES
CHARTERED ACCOUNTANTS

M/S Q-LINE BIOTECH PRIVATE LIMITED


DATE - -06/09/2022
LUCKNOW

UDIN:- 22406804BCCTKV8502


FRN NO. 022941C


(Mayank Mehrotra)
(Partner)
MEM. NO. 406804

Q-LINE BIOTECH PRIVATE LIMITED


Director

Q-LINE BIOTECH PRIVATE LIMITED


Director

Director

Director

STATEMENT OF PROFIT AND LOSS
Name of the company - M/S Q-LINE BIOTECH PRIVATE LIMITED
(Formerly known as M/s POCT Services Pvt. Ltd.)
Consolidated Profit & Loss statement for the year ended 31st March, 2022

Particulars	Note No	In Lakh (₹) 31/03/2022	In Lakh (₹) 31/03/2021
		Figures as at the end of current reporting period	Figures as at the end of current reporting period
I. Revenue from operations	15	30,417.90	17,141.13
II. Other Income	21	141.20	44.37
III. Total Revenue (I +II)		30,559.09	17,185.50
<u>IV. Expenses:</u>			
Cost of materials consumed			
Purchase of Stock-in-Trade	16	15,268.55	11,139.94
Changes in inventories of finished goods, work-in-progress and Stock-in-trade	17	-642.24	-388.38
Employee benefit expense	18	2,410.45	2,073.54
Financial costs	19	300.49	243.27
Depreciation and amortization expense		129.57	93.49
Other expenses	20	5,964.16	2,170.79
Total Expenses		23,430.98	15,332.66
V. Profit before exceptional and extraordinary items and tax	(III-IV)	7,128.11	1,852.84
VI. Exceptional Items		-	-
VII. Profit before extraordinary items and tax (V - VI)		7,128.11	1,852.84
VIII. Extraordinary Items		-	-
IX. Profit before tax (VII - VIII)		7,128.11	1,852.84
X. Tax expense:			
(1) Current tax		1,626.50	480.29
(2) Deferred tax		-	4.11
XI. Profit(Loss) from the period from continuing operations	(VII-VIII)	5,501.61	1,368.45
XVI. Earning per equity share:			
(1) Basic		0.0037	0.0009
(2) Diluted		0.0037	0.0009

AUDIT REPORT

" AS PER OUR SEPARATE REPORT OF EVEN DATE ANNEXED"

FOR MAYANK MEHROTRA & ASSOCIATES
CHARTERED ACCOUNTANTS

FRN NO. 022941C

(Mayank Mehrotra)
(Partner)
MEM. NO. 406804

M/S Q-LINE BIOTECH PRIVATE LIMITED

Q-LINE BIOTECH PRIVATE LIMITED

Saurabh Charya
Director

Q-LINE BIOTECH PRIVATE LIMITED

Amrita Charya
Director

Director

Director

DATE - -06/09/2022

LUCKNOW

UDIN:- 22406804BCCTKV8502

Name of the company - M/S Q-LINE BIOTECH PRIVATE LIMITED

(Formerly known as M/s POCT Services Pvt. Ltd.)

NOTES TO ACCOUNTS

		In Lakh (₹)	In Lakh (₹)
Particulars		Figures as at the end of current reporting period 31.03.2022	Figures as at the end of current reporting period 31.03.2021
1 Share Capital			
Equity Share Capital			
Authorised Share Capital		400.00	400.00
Issued, Subscribed And Fully Paid Share Capital (1 5,00,000 Shares Of Rs 10 Each)			
Amita Garg'S Capital A/C (30000 Shares Of Rs. 10 Each)		3.00	3.00
Pushplata Garg'S Capital A/C (7500 Shares Of Rs. 10 Each)		0.75	0.75
Saurabh Garg'S Capital A/C (1462500 Shares Of Rs. 10 Each)		146.25	146.25
Ajay Kumar Mahantany		7.50	6.00
Total		157.50	156.00
2 Reserve And Surplus			
Security Premium Account			
Opening Balance		4,556.87	3,078.68
Add:- Current Year Profit		5,501.61	1,376.66
Less Gst		1.29	-
Securities Premium Account		61.05	-
Vat Form -38		-1.36	-
Interest & Demond On Gst		-0.14	-
Interest On Tds		-0.81	-
Income Tax 2020-21		-78.19	-
Provision Income Tax 2020-21		2.38	-
Less: Income Tax F.Y 2018-19		-	-0.01
Custom Penalty		-	-0.66
Custom Duty Fine		-	-0.05
Interest & Demond On Gst		-	-1.48
Advance Custom Duty W.O		-	-0.35
Interest On Custom Duty		-	-0.11
Penalty By Rmscl		-	-6.59
Custon Duty Refundable		-	-0.32
Advance Tax 2019-20		-	-50.00
Add-Provision Income Tax 2019-20 W.O		-	140.05
Securities Premium Account		-	34.41
Self Assessment Tax For A.Y. 2020-21		-	-49.59
Derecognition Of Share Loss For Trasnaction Of Associate Company		-	36.24
Total		10,042.71	4,556.87
3 Long-Term Borrowings			
Secured			
HDFC Auto Loan No 65975585		9.92	14.03
HDFC Auto Loan No 48441288		0.37	1.41
Aditya Birla Finance Ltd (Abfllnwbil0000121526)		33.03	47.90
HDFC Bank Loan (116521353)		-	153.50
HDFC Bank Loan (123528448)		4.55	-
HDFC Bank Loan (123528754)		4.55	-



	HDFC Bank Loan (8120811)		174.57	225.94
	HDFC Bank Loan (127704052)		185.00	-
	HDFC Bank Loan (85927388)		76.12	-
	HDFC Bank Loan Gecl Ex-452541751		327.28	-
	Indusind Bank New Loan 162754		33.41	46.92
	Business Loan		-	-
	Magma Fincorp Ltd (Ps/0043/P/19/000008)		13.41	19.40
	India Infoline Finanance		-	2.82
	Fortune Credit Capital Limited (42760400000024)		11.19	24.12
	Fullerton India Loan (027702410771269)		20.63	29.64
	Capital First Ltd A/C No. 15929906		-	13.23
	India Bull lvi Finanance S000318285		-	6.18
	Unsecured Loans			
	Saurabh Garg Unsecured Loan		43.89	46.14
	Amita Garg Unsecured Loan		44.41	44.41
	Abhay Agarwal Unsecured Loan		19.00	19.00
			-	-
	Total		1,001.33	694.64
4	Short-Term Borrowings			
	Secured			
	ICICI Bank Ltd (628105034776)		2.55	-
	HDFC Bank (50200038045582) (Od)		3,339.05	1,872.34
	Total		3,341.60	1,872.34
5	Trade Payables			
	Trade Payables		3,466.06	1,905.37
	Total		3,466.06	1,905.37
6	Other Current Liabilities			
	Salary Payable		14.74	89.93
	Employee Pf & Esi		3.56	3.95
	Employer Contribution Pf Payable		3.21	2.83
	Pf Admin Charges Payable		0.14	0.14
	Lab Expenses Payable		-	0.99
	Office Expenses Payable		1.04	0.61
	Advance From Debtors		-	21.83
	Donation Payable		0.64	0.64
	Audit Fee Payable		0.67	1.42
	Gst Payable		-0.15	53.19
	Consultancy Payable		3.04	1.95
	Other Creditors		296.42	63.78
	Director'S Renumeration Payable		93.57	14.93
	Poct Services Loan A/C		0.23	-
	Travelling Payable		42.06	27.21
	Service Payable		-	0.14
	Tds On Commission		7.75	0.02
	Tds On Consultancy		4.18	0.39
	Tds On Contract Liabilities		8.99	0.57
	Tds On Cash Withdraw Recivable		-	0.01



	Tds On Salary	57.47	140.78
	Tds On Rent	0.79	0.62
	Tds U/S 195	-	0.45
	Tds On Purchase (194Q)	0.29	-
	Tds On Technical Serices (194J)	1.42	-
	Tcs On Amount Received	0.25	2.19
	Rent Payable	-	0.41
	Icici Lombard General Insurance Ltd.	2.65	3.36
	Trade Payables	5.94	3.95
	Commission Payable	0.08	0.08
	Shubham Diagnostics (Security Agst Machine)	-	3.00
	Security From Swastik Biotech (Rental Machine)	10.00	10.00
		-	-
	Total	558.98	449.37
7	Short-Term Provisions		
	Provision For Income Tax	1,626.50	480.29
	Less: Advance Tax	-975.00	-150.00
	Less : Tds & Tcs	-21.99	-11.69
	Total	629.50	318.60
8	Tangible Assets		
	Land/Building/Plant & Equipment/Furniture & Fixtures/ Vehicles/Office Equipment/Others(Individually)		
	Opening Balance	744.35	668.66
	Add: Acquisition	325.26	169.18
	Sub Total	1,069.61	837.84
	Less: Disposals		
	Gross Block At Year End(A)	1,069.61	837.84
	Less: Depreciation		
	Opening Depreciation		
	Depreciation For The Year	129.57	93.49
	Total Accumulated Depreciation(B)	-	
	Net Carrying Value (A) - (B)	940.04	744.35
	Total	940.04	744.35
9	Long Term Loans And Advances		
	Security Deposits	287.59	196.32
	Advance To Staff	18.19	-
	Ambicon State Chapter	0.20	-
	Loan To Poct Science House Private Limited	322.20	-
	Total	628.19	196.32
10	Current Investemnts		
	Poct Science House Pvt Ltd	757.24	-36.24
		757.24	-36.24
11	Inventories		
	Finished Goods	3,762.59	3,120.35
	Total	3,762.59	3,120.35
12	Trade Receivables		
	Secured/Unsecured/Doubtful	4,303.45	3,025.88



		Total	4,303.45	3,025.88	
13	Cash And Cash Equivalents				
	Balances With Banks		4,592.95	207.59	
	Cash In Hand		60.76	68.32	
	Total		4,653.71	275.91	
14	Other Current Assets:-				
	Advance Custom Duty Charges		-	2.28	
	Advance Infoline Loan		-	0.73	
	Amount Under Dispute		1.06	1.06	
	Commission Recivable From Draeger Medical India Pvt		5.25	5.25	
	Dd Fdr Emd		3,361.61	1,748.18	
	Deferred Revenue Expense		1.79	1.79	
	Extra Loan Payment		0.10	-	
	Gst Recivables		86.70	-	
	Interest On Fdr Accrued		101.86	39.21	
	Loans & Advances		-	393.62	
	Manpower Receivable		0.10	0.10	
	Preliminary Expenses		-	0.48	
	Office Exp Receivables		0.91	-	
	Other Current Assets		0.02	-	
	Prepaid		19.32	13.44	
	Rent Receivables		4.08	-	
	Retention Money		44.87	44.87	
	Science House Medicals Pvt Ltd		37.50	37.50	
	Security Import		2.20	0.40	
	Security Deposit To Gs1 India		0.03	0.03	
	Sperogenx Biosciences Pvt Ltd-(Bangalore)		28.18	28.18	
	Tcs On Purchase Of Goods		2.68	-	
	Tcs Surplus		0.08	0.00	
	Tds On Contract Surplus		-	0.04	
	Tds On Gst		61.65	79.54	
	Tds & Tcs 2021-222		21.05	-	
	Tds Surplus Paid		6.27	-	
	Vat Form 31		-	1.36	
	Yamuna Expressway Industrial Development Authority		350.47	177.65	
	Total		4,137.79	2,575.71	
15	Revenue From Operations(For Companies Other Than A Finance Company)				
	Revenue From- Sale Of Products		30,654.16	19,530.52	
	Revenue From- Sale Of Products - Inter Branch		-3,060.80	-3,227.78	
	Sale Of Services		244.64	271.11	
	Operating Revenues Wrt To Associated Pshpl (As Per Annexure-1)		2,579.89	567.28	
	Total		30,417.90	17,141.13	



16	Purchase Of Stock In Trade			
	Purchases		18,329.35	14,367.72
	Purchase - Interbranch		-3,060.80	-3,227.78
			15,268.55	11,139.94
17	Changes In Inventories Of Finished Goods, Work-In-Progress And Stock-In-Trade			
	Opening Stock		3,120.35	2,731.97
	Less:- Closing Stock		3,762.59	3,120.35
			-642.24	-388.38
18	Employee Benefits Expense			
	Salaries And Wages-Staff		1,660.45	1,329.54
	Director'S Remuneration		750.00	744.00
			2,410.45	2,073.54
	Total			
19	Finance Costs			
	Interest Expense		271.02	208.58
	Bank Charges		29.47	34.69
			300.49	243.27
	Total			
20	Other Expenses			
	Amc Charges		44.45	41.64
	Advertise And Publicity Exp		2.76	0.37
	Application Charges		-	0.24
	Freight Charges		10.56	6.82
	Freight Inward @ 5%		-	0.01
	Legal Expenses		39.13	20.04
	Audit Fees		1.19	0.37
	Cng / Petrol Charges		0.48	-
	Commission Expense		699.44	90.05
	Consultancy Charges		163.62	65.96
	Civil Work Expense		-	19.91
	Detention Charges @ 18%		1.88	2.78
	Air Freight Service @ 0%		241.93	119.11
	Freight Inward @ 12%		1.54	0.56
	Freight Inward @ 18%		0.88	2.44
	Clearing And Forwarding Services @ 18%		97.34	15.56
	Cargo Handling Services		1.40	-
	Do Revalidation Charges		-	0.01
	Demurrage Charges		-	0.01
	Freight(Gta) Service		7.35	1.62
	Calibration Expenses		0.63	-
	Concor Charges		11.02	3.11
	Water Transport Services Of Goods 5%		117.74	4.13
	Factory Consumables		21.96	19.06
	Factory Exp		29.66	27.30
	Carriage Inward-12%		0.82	-
	Custom Clearance Charges-18%		123.18	72.87



Packing & Forwarding Charges	86.67	43.42
Professional Fees @ 18%	2.55	-
Research & Development Expenses	10.91	92.24
Royalty Fee Project Prom	176.40	-
Sales & Marketing Exp	284.72	-
Shipping Line Charges @ 18%	-	1.93
Terminal Handling Charges @ 18%	0.55	0.50
Credit Reporting & Rating Services	-	-
Carriage Inward @ 18%	1.22	0.33
Processing Charges @18 %	-	0.02
Do Charges @ 18%	6.49	6.53
Do Charges (Not Taxable)	0.99	0.08
Generator Rental	1.20	-
Gem Prortal Fee	-	15.14
Insurance Charges 18%	-	0.48
Insurance Charges	36.04	27.72
Installation Charges	0.35	0.07
Loan Processing Fees	0.08	-
Man Power Service	-	0.67
Outward Freight (Gta) Service	-	6.24
Other Custom Charges	0.29	0.12
Consumables	0.01	-
Repair And Maintenance	137.36	16.19
Container Handling Charges	0.31	-
Company'S Esic Exp	-	0.00
Meeting Expenses	5.48	3.29
Misc Expenses	23.49	7.96
Mobile And Telephone Exp	0.45	-
Courier Expense	417.59	194.05
Conveyance	3.70	3.14
Donation	-	5.00
Csr Expense	65.65	39.18
Office Expenses	6.17	10.09
Labour Charges	-	7.33
Lab Exp	-	2.25
Liquidated Damage (Ld) Charges	3.12	53.24
Custom Duty	2.04	-
Disposal Of Biomedical Waste	-	0.42
Electricity Expenses	44.38	26.66
Employer Contribution Pf & Esic	38.70	35.12
Expired Goods	433.35	-
Festival Expenses	1.16	2.11
Hotel & Fooding Expenses	14.59	8.12
Software Maintenace Expenses	50.37	13.43
Service Charge Expenses	-	-
Telephone Expenses	0.78	1.53
Tender Expenses	-	5.07
Air Freight Export (Not Taxable)	28.62	-
Travelling Expenses	254.48	186.81
Transportaion Expenses	0.76	0.04
Pf Admin Charges	-	1.55
Processing Fees	0.42	-



	Techniquial Expenses	62.00	-
	Staff Welfare Exp	3.23	2.81
	Vehicle Repair & Main Charges	0.93	1.10
	Recruitment Charges	28.07	0.29
	Recruitment Charges (Manpower) @ 18%	21.30	-
	Stamp Duty	0.07	-
	Interest On Custom Duty	0.03	0.02
	Lab Coat	-	0.28
	Membership Fees	0.10	0.20
	Rent	106.85	97.84
	Registration Fees (Fda)	4.74	4.55
	Forex Commision Charges	2.69	3.59
	Forex Conversion Charges	12.02	22.18
	Foreign Exchange Loss	35.53	88.91
	Gst Exp(Ineligible)	25.75	0.02
	Interest On Gst	0.54	-
	Drug License Fee	-	0.16
	Printing & Stationery	30.89	12.79
	Preliminary Expenses W/Off	0.48	0.48
	Write Off	-	-
	Trade Fare Fees	41.68	-
	Employee Health Insurance	-	-
	Expenses Wrt Associated Pshpl (As Per Annexure-2)	1,826.86	603.53
	Total	5,964.16	2,170.79
21	Other Incomes		
	Fdr Interest	69.64	44.37
	Discount Received	0.09	-
	Misc Income (18%)	26.31	-
	Income From Rent @ 18%	5.32	-
	Freight Outward	35.63	-
	Other Revenues Wrt To Associated Pshpl (As Per Annexure-1)	4.21	-
		-	-
	Total	141.20	44.37



M/S Q-LINE BIOTECH PRIVATE LIMITED
(FORMERLY KNOWN AS M/S POCT SERVICES PVT. LTD.)
Notes Forming Part of Balance Sheet

(A) Trade Receivables : Ageing schedule as at 31st March, 2022:-

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	4,128.36	129.11	20.12	12.92	12.95	4,303.45
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables - considered good	-	-	-	-	-	-
(iv) Disputed trade receivables - considered doubtful	-	-	-	-	-	-

(B) Trade Receivables : Ageing schedule as at 31st March, 2021:-

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	2,202.85	715.64	46.30	33.47	27.62	3,025.88
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables - considered good	-	-	-	-	-	-
(iv) Disputed trade receivables - considered doubtful	-	-	-	-	-	-

(C) Trade payables : Ageing schedule as at 31st March, 2022:-

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade Payables - considered good	2,208.10	972.46	222.15	44.38	18.98	3,466.06
(ii) Undisputed Trade Payables - considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Payables - considered good	-	-	-	-	-	-
(iv) Disputed Trade Payables - considered doubtful	-	-	-	-	-	-

(D) Trade payables : Ageing schedule as at 31st March, 2021:-

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade Payables - considered good	1,266.69	534.32	74.38	29.98	-	1,905.37
(ii) Undisputed Trade Payables - considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Payables - considered good	-	-	-	-	-	-
(iv) Disputed Trade Payables - considered doubtful	-	-	-	-	-	-



SIGNIFICANT ACCOUNTING POLICIES & NOTES ON CONSOLIDATED FINANCIAL STATEMENTS

1. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements relate to **Q Line Biotech Private Limited (Formerly known as POCT Services Pvt. Ltd.)**, and one of its Associate Company- POCT Science House Pvt. Ltd. (collectively referred to as "the Group"). The consolidated financial statements have been prepared on the following basis:

- a) Investment in Associate Company has been accounted for under the Equity method as per Accounting Standard (AS)-23 – "Accounting for Investments in Associates in Consolidated Financial Statements".
- b) There is no difference between the cost of investment in the associates and the share of net assets at the time of acquisition of shares in the associates, so no Goodwill/Capital Reserve has been recognized to that effect in the financial statements. Also, post acquisition profit/Loss has been added to the investment made in Associate Company.
- c) As far as possible, the consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented in the same manner as the company's separate financial statements.

2. Other significant accounting policies

These are set out under "Significant Accounting Policies" as given in the Company's separate financial statements and some of the other accounting policies which are material and are affecting the accounting policies & financial statements of the group as a whole have been given below:

1. Basis for Accounting :

As defined in Accounting Standard -1 (AS-1) issued by the Institute of Chartered Accountant of India and which is mandatory in nature. The company follows mercantile system of accounting and recognizes income and expenditure on accrued basis.

These accounts are prepared on historical cost of basis as a going concern and are consistent with the generally accepted Accounting Principles.

2. Property Plant and Equipment and Intangible Assets

The Property Plant and Equipment are shown at historical cost less accumulated depreciation.

3. Depreciation:

Depreciation on fixed assets has been calculated as per provisions under the Companies Act, 2013, on written down value method..

4. Inventories:

Inventories are valued at cost.

5. Revenue Recognition:-

In Case of Holding Company and its Associates - as per Accounting Standard – 9 (AS -9) issued by Institute of Chartered Accountants of India the Income / revenue has been recognized on accrual basis.



- (a) Sales are booked net of trade discount after adjusting sales returns and trade tax.
- (b) Insurance Claims lodged by the holding company are accounted for in the year of its settlement.
- (c) Other / Misc. revenues are recognized, when the amount and its collectivity is certain.
- (d) Interest payable / receivable are being accounted for on accrual basis.

10. EXPENDITURE ON EMPLOYEES:

The holding company has paid fixed monthly remuneration to the Directors as per Companies Act, 2013.

DIRECTORS REMUNERATION

PARTICULARS	AMOUNT	NO. OF DIRECTORS
Salaries	7,50,00,000.00	7
Bonus	NIL	
TOTAL	NIL	7
(Previous Year)		

	Previous Year	Current Year
a) Audit fees	37,000.00	1,19,000.00

11. ADDITIONAL NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

A. Disclosure requirements as per Accounting Standards (AS)- 21& 23 issued by ICAI:

B. Investment in Associate Enterprise:

The Group's Associate Company is as under:

Name	Country of Incorporation	Percentage of ownership interest as at 31 st March'2022	Percentage of ownership interest as at 31 st March'2021
POCT Science House Pvt. Ltd.	India	50%	50%

Date: 06/09/2022
Place: Lucknow


For Mayank Mehrotra & Associates
Chartered Accountants

FR No. 022941C



(Mayank Mehrotra)
(Partner)
M No. 406804

For M/s Q Line Biotech
Private Limited

Q-LINE BIOTECH PRIVATE LIMITED


Director
(Director)

Q-LINE BIOTECH PRIVATE LIMITED


Director
(Director)